ONCOMATRYX

Modulating the tumor microenvironment

ONCOMATRYX

Modulating the tumor microenvironment

Innovation. Eagerness. Hope

More than just a biotech company.
A multidisciplinary team committed to science, medicine and cancer patients.
Find out more about our history

A new avenue to reach metastatic solid tumors

Our founder, Laureano Simón, envisioned a new approach to target tumor resistance to conventional treatments. It was not about fighting the tumor, but understanding and targeting its microenvironment.

In the war on cancer, our battlefield is the tumor stroma.
Learn more about our approach

Our commitment

We are exploring new horizons in the war on cancer. We envision a new era where cancer will be beaten with orchestrated combinations of precision drugs targeting the tumor and its microenvironment.

Together, we are relentlessly pursuing solutions once deemed impossible, bringing hope to patients.
Our values

Tumor microenvironment-targeted ADCs

Clinical trials

If you are an investigator

Explore the progress of our clinical trials. OMTX705 clinical trials began the journey in 2022.

Clinical trials

If you are a patient

Find out why joining a clinical trial.

Clinical trials

KEEP UP TO DATE WITH THE LATEST NEWS